Us Bancorp \De\ Immuneering Corp Call Options Transaction History
Us Bancorp \De\
- $74.1 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMRX
# of Institutions
43Shares Held
4.42MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.33 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD767KShares$966,5760.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$672,0380.0% of portfolio
-
Morgan Stanley New York, NY454KShares$572,1660.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY215KShares$270,9001.71% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $33.3M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...